The hook effect in macroprolactinomas: tumor size thresholds, prolactin patterns, and clinical consequences - a

Prashant Yadav1, Amir H Hamrahian1, Roberto Salvatori2

  • 1Division of Endocrinology, Diabetes and Metabolism, and Pituitary Center Johns Hopkins, University School of Medicine, Baltimore, MD, 21287, USA.

Pituitary
|May 29, 2026
PubMed
Abstract

Insights

The hook effect in macroprolactinoma assays can cause falsely low prolactin (PRL) levels, leading to misdiagnosis. Serial dilution testing is crucial for pituitary macroadenoma to prevent unnecessary surgery and ensure timely treatment.

Area of Science:

  • Endocrinology
  • Clinical Chemistry
  • Oncology

Background:

  • The immunoassay hook effect can lead to spuriously low prolactin (PRL) measurements in patients with macroprolactinomas.
  • This can result in misdiagnosis and inappropriate patient management.

Purpose of the Study:

  • To determine the tumor size threshold for the hook effect in macroprolactinomas.
  • To characterize pre-dilution PRL patterns and quantify PRL underestimation.
  • To assess the clinical consequences of unrecognized hook effect.

Main Methods:

  • Systematic review of PubMed, Embase, Scopus, Google Scholar, and Web of Science (Jan 2000-Aug 2025).
  • Included studies reporting individual patient data with confirmed hook effect (pre- and post-dilution PRL, tumor size, serial dilution confirmation).
  • Data synthesized using individual patient data (IPD) quantitative methods; registered on PROSPERO.

Main Results:

  • 23 patients from 14 studies; median tumor diameter 48.0 mm (range 22-100 mm).
  • Hook effect occurred in 39.1% of tumors below the 40 mm giant adenoma threshold.
  • Median pre-dilution PRL 100.0 ng/mL, median post-dilution PRL 6,460.0 ng/mL (median 64.7× increase).
  • Unrecognized hook effect led to unnecessary surgery in 55.6% of cases.

Conclusions:

  • Pre-dilution PRL values can mimic stalk effect, necessitating further investigation.
  • Serial dilution testing is recommended for pituitary macroadenoma with disproportionately low PRL relative to tumor size.
  • This prevents misdiagnosis, unnecessary surgery, and delays in dopamine agonist therapy.